Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JADE: Phase II Trial in Patients With Geographic Atrophy: A Randomized, Double-masked, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of BI 1584862

Next Previous
Trial Profile

JADE: Phase II Trial in Patients With Geographic Atrophy: A Randomized, Double-masked, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of BI 1584862

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BI 1584862 (Primary)
  • Indications Age-related macular degeneration; Dry macular degeneration
  • Focus Therapeutic Use
  • Acronyms JADE
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 19 Aug 2025 Planned End Date changed from 31 Dec 2026 to 26 Feb 2027.
  • 19 Aug 2025 Planned primary completion date changed from 15 Dec 2026 to 15 Feb 2027.
  • 06 May 2025 According to a Boehringer Ingelheim media release, Karl Csaky is principal investigator of this phase II trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top